肝细胞-胆管细胞癌合并症的危险因素：一项基于医院的病例对照研究。
Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.
作者信息
Zhou Yan-Ming, Zhang Xiao-Feng, Wu Lu-Peng, Sui Cheng-Jun, Yang Jia-Mei
机构信息
Yan-Ming Zhou, Lu-Peng Wu, Department of Hepato-Biliary-Pancreato-Vascular Surgery, the First Affiliated Hospital of Xiamen University, Xiamen 361003, Fujian Province, China.
出版信息
World J Gastroenterol. 2014 Sep 21;20(35):12615-20. doi: 10.3748/wjg.v20.i35.12615.
Abstract
AIM
To identify risk factors contributing to the development of combined hepatocellular-cholangiocarcinoma (CHC) in China.
METHODS
One hundred and twenty-six patients with CHC and 4:1 matched healthy controls were interviewed during the period from February 2000 to October 2012. Logistic regression analysis was used to calculate odds ratios (OR) and 95% confidence intervals (CI) for each risk factor.
RESULTS
Univariate analysis showed that the significant risk factors for CHC development were hepatitis B virus (HBV) infection, heavy alcohol consumption, a family history of liver cancer, and diabetes mellitus. Multivariate stepwise logistic regression analysis showed that HBV infection (OR = 19.245, 95%CI: 13.260-27.931) and heavy alcohol consumption (OR = 2.186, 95%CI: 1.070-4.466) were independent factors contributing to the development of CHC.
CONCLUSION
HBV infection and heavy alcohol consumption may play a role in the development of CHC in China.
摘要
目的
确定在中国导致肝细胞-胆管细胞癌（CHC）发生的危险因素。
方法
在2000年2月至2012年10月期间，对126例CHC患者和4:1匹配的健康对照进行了访谈。采用逻辑回归分析计算每个危险因素的比值比（OR）和95%置信区间（CI）。
结果
单因素分析显示，CHC发生的显著危险因素为乙型肝炎病毒（HBV）感染、大量饮酒、肝癌家族史和糖尿病。多因素逐步逻辑回归分析显示，HBV感染（OR = 19.245，95%CI：13.260 - 27.931）和大量饮酒（OR = 2.186，95%CI：1.070 - 4.466）是导致CHC发生的独立因素。
结论
HBV感染和大量饮酒可能在中国CHC的发生中起作用。
相似文献
1
Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.
World J Gastroenterol. 2014 Sep 21;20(35):12615-20. doi: 10.3748/wjg.v20.i35.12615.
2
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study.
Am J Gastroenterol. 2007 May;102(5):1016-21. doi: 10.1111/j.1572-0241.2007.01104.x. Epub 2007 Feb 23.
3
Risk factors of intrahepatic cholangiocarcinoma in patients with hepatolithiasis: a case-control study.
Hepatobiliary Pancreat Dis Int. 2011 Dec;10(6):626-31. doi: 10.1016/s1499-3872(11)60106-9.
4
Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type.
Hum Pathol. 2017 Jun;64:118-127. doi: 10.1016/j.humpath.2017.01.016. Epub 2017 Apr 18.
5
Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy.
Cancer Causes Control. 2001 Dec;12(10):959-64. doi: 10.1023/a:1013747228572.
6
Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study.
Am J Gastroenterol. 2008 Jul;103(7):1716-20. doi: 10.1111/j.1572-0241.2008.01796.x. Epub 2008 Jun 28.
7
Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: a case-control study in Korea.
World J Gastroenterol. 2015 Jan 14;21(2):502-10. doi: 10.3748/wjg.v21.i2.502.
8
Combined hepatocellular cholangiocarcinoma: a case report and review of literature.
Dig Dis Sci. 2013 Jul;58(7):2114-23. doi: 10.1007/s10620-013-2585-1. Epub 2013 Feb 9.
9
Debating the presentation, morphology, origin, and prognosis of a combined hepatocellular-cholangiocarcinoma.
Dig Dis Sci. 2013 Aug;58(8):2423-4. doi: 10.1007/s10620-013-2720-z. Epub 2013 May 22.
10
The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
Int J Med Sci. 2021 Jan 1;18(1):187-198. doi: 10.7150/ijms.50883. eCollection 2021.
引用本文的文献
1
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management.
Liver Cancer. 2023 Apr 24;13(1):6-28. doi: 10.1159/000530700. eCollection 2024 Feb.
2
Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma.
Front Oncol. 2023 Jul 21;13:1234113. doi: 10.3389/fonc.2023.1234113. eCollection 2023.
3
Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma.
Abdom Radiol (NY). 2023 Jun;48(6):2019-2037. doi: 10.1007/s00261-023-03879-0. Epub 2023 Mar 24.
4
The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma-State of the Art and Future Perspectives.
Cancers (Basel). 2023 Jan 1;15(1):301. doi: 10.3390/cancers15010301.
5
Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.
Hepatol Int. 2022 Dec;16(6):1339-1352. doi: 10.1007/s12072-022-10419-3. Epub 2022 Sep 20.
6
A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab.
Clin Case Rep. 2022 Jul 25;10(7):e6129. doi: 10.1002/ccr3.6129. eCollection 2022 Jul.
7
Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know.
Diagnostics (Basel). 2022 Apr 2;12(4):890. doi: 10.3390/diagnostics12040890.
8
Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma.
Cancers (Basel). 2021 Jul 2;13(13):3336. doi: 10.3390/cancers13133336.
9
Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma.
World J Hepatol. 2020 Nov 27;12(11):1020-1030. doi: 10.4254/wjh.v12.i11.1020.
10
New insights into the pathophysiology and clinical care of rare primary liver cancers.
JHEP Rep. 2020 Aug 24;3(1):100174. doi: 10.1016/j.jhepr.2020.100174. eCollection 2021 Feb.
本文引用的文献
1
Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
Am J Surg Pathol. 2013 Apr;37(4):496-505. doi: 10.1097/PAS.0b013e31827332b0.
2
Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China.
Carcinogenesis. 2013 Aug;34(8):1800-5. doi: 10.1093/carcin/bgt007. Epub 2013 Jan 14.
3
Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma.
Surg Oncol. 2013 Mar;22(1):55-60. doi: 10.1016/j.suronc.2012.09.003. Epub 2012 Oct 24.
4
Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers.
J Gastroenterol Hepatol. 2013 Jan;28(1):122-7. doi: 10.1111/j.1440-1746.2012.07289.x.
5
Parallel induction of cell proliferation and inhibition of cell differentiation in hepatic progenitor cells by hepatitis B virus X gene.
Int J Mol Med. 2012 Oct;30(4):842-8. doi: 10.3892/ijmm.2012.1060. Epub 2012 Jul 12.
6
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27.
7
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma.
J Hepatol. 2012 Jul;57(1):69-76. doi: 10.1016/j.jhep.2012.02.022. Epub 2012 Mar 13.
8
Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
J Gastroenterol. 2012 May;47(5):577-85. doi: 10.1007/s00535-011-0522-7. Epub 2012 Jan 11.
9
Clinicopathological analysis of 14 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
Hepatobiliary Pancreat Dis Int. 2011 Dec;10(6):620-5. doi: 10.1016/s1499-3872(11)60105-7.
10
Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor.
Ann Surg Oncol. 2012 May;19(5):1628-36. doi: 10.1245/s10434-011-2150-0. Epub 2011 Nov 24.
Zotero 插件